TELA BIO ($TELA) posted quarterly earnings results on Thursday, March 20th. The company reported earnings of -$0.23 per share, missing estimates of -$0.23 by $0.00. The company also reported revenue of $17,650,000, missing estimates of $23,629,728 by $-5,979,728.
You can see Quiver Quantitative's $TELA stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
TELA BIO Insider Trading Activity
TELA BIO insiders have traded $TELA stock on the open market 4 times in the past 6 months. Of those trades, 4 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $TELA stock by insiders over the last 6 months:
- ANTONY KOBLISH (Chief Executive Officer) purchased 88,888 shares for an estimated $199,998
- ROBERTO CUCA (COO and CFO) purchased 64,444 shares for an estimated $144,999
- PAUL TALMO (Chief Technology Officer) purchased 22,222 shares for an estimated $49,999
- GREGORY A. FIRESTONE (Chief Commercial Officer) purchased 6,666 shares for an estimated $14,998
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
TELA BIO Hedge Fund Activity
We have seen 31 institutional investors add shares of TELA BIO stock to their portfolio, and 47 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ORBIMED ADVISORS LLC removed 2,161,185 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $6,526,778
- SILVERARC CAPITAL MANAGEMENT, LLC added 1,940,721 shares (+172.5%) to their portfolio in Q4 2024, for an estimated $5,860,977
- NANTAHALA CAPITAL MANAGEMENT, LLC added 1,764,600 shares (+92.1%) to their portfolio in Q4 2024, for an estimated $5,329,092
- DAFNA CAPITAL MANAGEMENT LLC added 1,441,029 shares (+inf%) to their portfolio in Q4 2024, for an estimated $4,351,907
- PARADIGM CAPITAL MANAGEMENT INC/NY removed 1,256,200 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $3,178,185
- STONEPINE CAPITAL MANAGEMENT, LLC added 1,243,099 shares (+112.0%) to their portfolio in Q4 2024, for an estimated $3,754,158
- ROYCE & ASSOCIATES LP added 1,000,064 shares (+inf%) to their portfolio in Q4 2024, for an estimated $3,020,193
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
TELA BIO Government Contracts
We have seen $176,800 of award payments to $TELA over the last year.
Here are some of the awards which we have have seen pay out the most over the last year:
- VENTRAL HERNIA: $17,500
- OVITEX 2S PERMANENT 25X40 CM: $17,500
- PROSTHETICS. SURGICAL REPAIR: $17,500
- MESH: $17,100
- PROSTHETICS-TISSUE "BILL ONLY": $15,960
To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.
TELA BIO Analyst Ratings
Wall Street analysts have issued reports on $TELA in the last several months. We have seen 2 firms issue buy ratings on the stock, and 1 firms issue sell ratings.
Here are some recent analyst ratings:
- Piper Sandler issued a "Overweight" rating on 10/23/2024
- Lake Street issued a "Underperform" rating on 10/04/2024
- Canaccord Genuity issued a "Buy" rating on 10/04/2024
To track analyst ratings and price targets for TELA BIO, check out Quiver Quantitative's $TELA forecast page.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
